The aberrant activation of estrogen/ER‐target gene program was considered as one of the main driving‐forces for ER‐positive breast cancer development as this gene program is implicated in cell cycle regulation, cell metabolism control, and immune response, among others. This evidence concerns the gene ESR1 and breast carcinoma.